Yi‐Tsung Lu

1.5k citations

28 papers · 1.0k indexed · h-index 13

Impact in

Cancer Research top 5%
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Oncology top 5%
- Cancer Cells and Metastasis

Papers in

Cancer Research 12
- Cancer Genomics and Diagnostics 10
Oncology 14
- Cancer Cells and Metastasis 9
- Cancer Immunotherapy and Biomarkers 5

Co-authors: Hsian‐Rong Tseng Shuang Hou Edwin M. Posadas Jie‐Fu Chen Leland W.K. Chung Zunfu Ke Jake Lichterman Millicent Lin
Journals: Journal of Clinical Oncology (8 papers)Clinical Cancer Research (2 papers)Advanced Materials (2 papers)Cancer (1 paper)Scientific Reports (1 paper)
Partner nations: United States China Spain

In The Last Decade

Yi‐Tsung Lu

26 papers receiving 1.0k citations

Peers

Countries citing papers authored by Yi‐Tsung Lu

Since Specialization

Citations

This map shows the geographic impact of Yi‐Tsung Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi‐Tsung Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi‐Tsung Lu more than expected).

Fields of papers citing papers by Yi‐Tsung Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi‐Tsung Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi‐Tsung Lu. The network helps show where Yi‐Tsung Lu may publish in the future.

Co-authors

The 25 scholars most cited alongside Yi‐Tsung Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yi‐Tsung Lu Line = papers co-authored together Yi‐Tsung Lu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). Journal of Clinical Oncology ·Thomas Powles, Michiel Simon Van Der Heijden, Yohann Loriot, Jens Bedke, Begoña P. Valderrama, Gopa Iyer, Eiji Kikuchi, Qian‐Xin Wu, Christof Vulsteke, Alexandra Drakaki, Steffen Rausch, Marcia Morales, Se Hoon Park, Umang Swami, Jian‐Ri Li, Seema Rao Gorla, Blanca Homet Moreno, Xuesong Yu, Yi‐Tsung Lu, Shilpa Gupta	2025	5
2	Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39. Journal of Clinical Oncology ·Jens Bedke, Michiel Simon Van Der Heijden, Thomas Powles, Begoña P. Valderrama, Eiji Kikuchi, Gopa Iyer, Christof Vulsteke, Umang Swami, Daniel Castellano, Naveed Sarwar, Alexandra Drakaki, Jean Hoffman‐Censits, Marcia Morales, Timur Andabekov, Jian‐Ri Li, Yi‐Tsung Lu, Xuesong Yu, Aditya Shetty, Blanca Homet Moreno, Shilpa Gupta	2024	2
3	Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Journal of Clinical Oncology ·Shilpa Gupta, Yong Li, Michiel Simon Van Der Heijden, Jens Bedke, Begoña P. Valderrama, Eiji Kikuchi, Aude Fléchon, Daniel P. Petrylak, Maria De Santis, Matt D. Galsky, Jae‐Lyun Lee, Umang Swami, Srikala S. Sridhar, Ugo De Giorgi, Phoebe Wright, Yi‐Tsung Lu, Xuesong Guan, Ester Juarez, Blanca Homet Moreno, Thomas Powles	2024	5
4	Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314 European Urology Oncology ·Yi‐Tsung Lu, Melissa Plets, Houjie Li, Ekaterina V. Mitrokhina, Steven Cen, Suhn K. Rhie, Kimberly D. Siegmund, Siamak Daneshmand, David I. Quinn, Joshua J. Meeks, Seth P. Lerner, Daniel P. Petrylak, David J. McConkey, Thomas W. Flaig, Ian M. Thompson, Amir Goldkorn	2023	22
5	Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis International Journal of Molecular Sciences ·Houjie Li, Jonathan D. Buckley, Dejerianne Ostrow, Bino Varghese, Steven Cen, S H Lee, Nolan G. Ericson, Ekaterina V. Mitrokhina, Yi‐Tsung Lu, Thaddeus C. George, Jeffrey W. Smith, David I. Quinn, Vinay Duddalwar, Timothy J. Triche, Amir Goldkorn	2022	12
6	FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer Cancers ·Yi‐Tsung Lu, Tong Xu, Stephanus Marthinus Rust, Stella Loukeri Woestman, Zhifei Luo, Gangning Liang, Peggy Farnham, Suhn K. Rhie, Amir Goldkorn	2022	11
7	Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype International Journal of Cancer ·Tong Xu, Hongtao Li, Jenny Wei, Meng Li, Stella Loukeri Woestman, Yi‐Tsung Lu, Ranjani Lakshminarasimhan, Rong Xu, 留美藤原, Houjie Li, Hemant Gujar, Suhn K. Rhie, Kimberly D. Siegmund, Gangning Liang, Amir Goldkorn	2020	11
8	<p>Current status of liquid biopsies for the detection and management of prostate cancer</p> Cancer Management and Research ·Yi‐Tsung Lu, wang haijun, I. I. Kovtun, Amir Goldkorn	2019	51
9	Gelatinous bone marrow transformation and emergence of clonal Philadelphia-negative cytogenetic abnormalities with excess blasts in a patient with chronic myeloid leukemia treated with dasatinib Anti-Cancer Drugs ·Esagbodje Ovoke Regina, Ali Nael, Yi‐Tsung Lu, Stanley Nwaonu, Russell K. Brynes, Э. Г. Цыремпилов, Mojtaba Akhtari	2019	2
10	NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells Advanced Drug Delivery Reviews ·Yu Jen Jan, Jie‐Fu Chen, Yazhen Zhu, Yi‐Tsung Lu, 裕子内藤, H. K. Kley, Matthew Smalley, José Luis Gonçalves Bretos, Jiantong Dong, Li-Ching Chen, Hsiao‐hua Yu, James S. Tomlinson, Shuang Hou, Vatche G. Agopian, Edwin M. Posadas, Hsian‐Rong Tseng	2018	82
11	Circulating tumor cells in prostate cancer: beyond enumeration. PubMed ·Jie‐Fu Chen, Yi‐Tsung Lu, Shirley Cheng, Hsian‐Rong Tseng, Robert A. Figlin, Edwin M. Posadas	2017	9
12	Applications of circulating tumor cells for prostate cancer Asian journal of urology ·Shirley Cheng, Jie‐Fu Chen, Yi‐Tsung Lu, Leland W.K. Chung, Hsian‐Rong Tseng, Edwin M. Posadas	2016	2
13	Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells Theranostics ·Jie‐Fu Chen, Yazhen Zhu, Yi‐Tsung Lu, Letícia Campos Siqueira, Shuang Hou, Vatche G. Agopian, James S. Tomlinson, Edwin M. Posadas, Hsian‐Rong Tseng	2016	43
14	miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer Clinical Cancer Research ·Sajni Josson, Murali Gururajan, Peizhen Hu, Chen Shao, Gina Chia‐Yi Chu, Haiyen E. Zhau, Chunyan Liu, Kaiqin Lao, Chia-Lun Lu, Yi‐Tsung Lu, Jake Lichterman, Srinivas Nandana, Quanlin Li, André Rogatko, Dror Berel, Edwin M. Posadas, Ladan Fazli, Dhruv Sareen, Leland W.K. Chung	2014	118
15	miR-154* and miR-379 in the DLK1-DIO3 MicroRNA Mega-Cluster Regulate Epithelial to Mesenchymal Transition and Bone Metastasis of Prostate Cancer Clinical Cancer Research ·Murali Gururajan, Sajni Josson, Gina Chia‐Yi Chu, Chia-Lun Lu, Yi‐Tsung Lu, Christopher L. Haga, Haiyen E. Zhau, Chunyan Liu, Jake Lichterman, Peng Duan, Edwin M. Posadas, Leland W.K. Chung	2014	82
16	A Translational Phase 2 Study of Cabozantinib in Men with Metastatic Castration Resistant Prostate Cancer with Visceral Metastases with Characterization of Circulating Tumor Cells and Large Oncosomes Annals of Oncology ·Edwin M. Posadas, Mourad Tighiouart, Yi‐Tsung Lu, Dolores Di Vizio, David Hoffman, M May, Kevin S. Scher, S. Contoli, Manal Stephan, Nancy P. Moldawer, Beatrice S. Knudsen, Michael R. Freeman, Neil A. Bhowmick, André Rogatko, Hsian‐Rong Tseng, Leland W.K. Chung, Robert A. Figlin	2014	1
17	Nanostructure Embedded Microchips for Detection, Isolation, and Characterization of Circulating Tumor Cells Accounts of Chemical Research ·Millicent Lin, Jie‐Fu Chen, Yi‐Tsung Lu, Yang Zhang, Jinzhao Song, Shuang Hou, Zunfu Ke, Hsian‐Rong Tseng	2014	177
18	Tumor Cell Isolation: High‐Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber‐Embedded Microchip for Whole Exome Sequencing (Adv. Mater. 21/2013) Advanced Materials ·Libo Zhao, Yi‐Tsung Lu, Fuqiang Li, Kui Wu, Shuang Hou, Juehua Yu, Qinglin Shen, Dongxia Wu, Min Song, Wei‐Han OuYang, Zhengyuan Luo, Tom Lee, Xiaohong Fang, Chen Shao, Xun Xu, Mitch A. Garcia, Leland W.K. Chung, Matthew B. Rettig, Hsian‐Rong Tseng, Edwin M. Posadas	2013	1
19	High‐Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber‐Embedded Microchip for Whole Exome Sequencing Advanced Materials ·Libo Zhao, Yi‐Tsung Lu, Fuqiang Li, Kui Wu, Shuang Hou, Juehua Yu, Qinglin Shen, Dongxia Wu, Min Song, Wei‐Han OuYang, Zhengyuan Luo, Tom Lee, Xiaohong Fang, Chen Shao, Xun Xu, Mitch A. Garcia, Leland W.K. Chung, Matthew B. Rettig, Hsian‐Rong Tseng, Edwin M. Posadas	2013	133
20	NanoVelcro Chip for CTC enumeration in prostate cancer patients Methods ·Yi‐Tsung Lu, Libo Zhao, Qinglin Shen, Mitch A. Garcia, Dongxia Wu, Shuang Hou, Min Song, Xiaochun Xu, Wei‐Han OuYang, Fan Hailin, Jake Lichterman, Zhengyuan Luo, Xuan Xuan, Jiaoti Huang, Leland W.K. Chung, Matthew B. Rettig, Hsian‐Rong Tseng, Chen Shao, Edwin M. Posadas	2013	96

About Yi‐Tsung Lu

Yi‐Tsung Lu is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Surgery and Biophysics, having authored 28 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (10 papers), Cancer Cells and Metastasis (9 papers), Bladder and Urothelial Cancer Treatments (8 papers), Prostate Cancer Treatment and Research (7 papers), Cancer Immunotherapy and Biomarkers (5 papers), Urinary and Genital Oncology Studies (5 papers), Epigenetics and DNA Methylation (4 papers) and 3D Printing in Biomedical Research (4 papers). The work is most often cited by research in Cancer Research (429 citations), Oncology (463 citations), Biomedical Engineering (396 citations), Molecular Biology (403 citations) and Pulmonary and Respiratory Medicine (165 citations). Yi‐Tsung Lu has collaborated with scholars based in United States, China and Spain. Frequent co-authors include Hsian‐Rong Tseng, Shuang Hou, Edwin M. Posadas, Jie‐Fu Chen, Leland W.K. Chung, Zunfu Ke, Jake Lichterman, Millicent Lin, Jinzhao Song and Yang Zhang. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Advanced Materials, Cancer and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact